secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2026-08-04T20:05:24+00:00
Accession:  0001438533-26-000062
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere Q2: FILSPARI sales +96% to $141M; FSGS launch drives 2,012 PSFs; net loss $34.8M
--------------------------------------------------------------------------------

- U.S. net product sales $161.4M in Q2 2026, up from $94.8M; FILSPARI sales $141.1M (+96% YoY).
- Net loss $34.8M ($0.37/share) vs $12.8M loss in Q2 2025; non-GAAP net loss $9.0M ($0.10/share).
- Cash $489.2M; issued $525M of 0.5% convertible notes due 2032, repurchased $221M of 2029 notes.
- In-licensed civorebrutinib from Everest Medicines for $112.5M upfront; plans to study in pMN, FSGS, MCD.
- Phase 3 HARMONY for pegtibatinase in HCU enrolling; topline data expected 2H 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853326000062/0001438533-26-000062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853326000062/tvtx-20260804.htm
  HTML page:      https://secwatch.observer/filing/0001438533-26-000062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer